These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 18791116)

  • 21. Nonalcoholic fatty liver disease and OGTT.
    Uygur-Bayramiçli O; Sargin M
    J Clin Gastroenterol; 2008 Feb; 42(2):219. PubMed ID: 18209601
    [No Abstract]   [Full Text] [Related]  

  • 22. Predictors of steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease.
    Pagadala M; Zein CO; McCullough AJ
    Clin Liver Dis; 2009 Nov; 13(4):591-606. PubMed ID: 19818307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Invasive and non-invasive investigations for non-alcoholic steatohepatitis (NASH): the need for biochemical markers.
    Ahmed MH
    Scand J Gastroenterol; 2006 Mar; 41(3):372. PubMed ID: 16497631
    [No Abstract]   [Full Text] [Related]  

  • 24. [Should we do a liver puncture biopsy in patients with chronic "unexplained" cytolyses?].
    De Lédinghen V
    Gastroenterol Clin Biol; 2002; 26(8-9):724-7. PubMed ID: 12434076
    [No Abstract]   [Full Text] [Related]  

  • 25. Association of serum gamma-glutamyltransferase and alanine aminotransferase activities with risk of type 2 diabetes mellitus independent of fatty liver.
    Kim CH; Park JY; Lee KU; Kim JH; Kim HK
    Diabetes Metab Res Rev; 2009 Jan; 25(1):64-9. PubMed ID: 19065605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of blood tests for liver fibrosis specific or not to NAFLD.
    Calès P; Lainé F; Boursier J; Deugnier Y; Moal V; Oberti F; Hunault G; Rousselet MC; Hubert I; Laafi J; Ducluzeaux PH; Lunel F
    J Hepatol; 2009 Jan; 50(1):165-73. PubMed ID: 18977552
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [On the value of the ceruloplasmin determination in the enzyme diagnosis of liver diseases].
    Lorentz K
    Schweiz Med Wochenschr; 1969 Apr; 99(16):600-2. PubMed ID: 5768020
    [No Abstract]   [Full Text] [Related]  

  • 28. Metabolic disturbances in non-alcoholic fatty liver disease.
    Byrne CD; Olufadi R; Bruce KD; Cagampang FR; Ahmed MH
    Clin Sci (Lond); 2009 Apr; 116(7):539-64. PubMed ID: 19243311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma reactive carbonyl species levels and risk of non-alcoholic fatty liver disease.
    Liu S; Shi W; Li G; Jin B; Chen Y; Hu H; Liu L; Xie F; Chen K; Yin D
    J Gastroenterol Hepatol; 2011 Jun; 26(6):1010-5. PubMed ID: 21265881
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation of fatty liver index and lipid accumulation product for predicting fatty liver in Korean population.
    Kim JH; Kwon SY; Lee SW; Lee CH
    Liver Int; 2011 Nov; 31(10):1600-1. PubMed ID: 22093336
    [No Abstract]   [Full Text] [Related]  

  • 31. Expanding the applicability of noninvasive fibrosis markers in HIV/HCV co-infected patients.
    Schiavon LL; Filho RJ; Narciso JL; Sampaio JP; Lanzoni VP; Ferraz ML; Silva AE
    Hepatology; 2007 Jan; 45(1):257-8. PubMed ID: 17187416
    [No Abstract]   [Full Text] [Related]  

  • 32. Rapid MRI using a modified Dixon technique: a non-invasive and effective method for detection and monitoring of fatty metamorphosis of the liver.
    Fishbein MH; Stevens WR
    Pediatr Radiol; 2001 Nov; 31(11):806-9. PubMed ID: 11692239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alanine aminotransferase/aspartate aminotransferase ratio reversal and prolonged prothrombin time: a specific indicator of hepatic cirrhosis.
    Siddiqi AI; Siddiqeh M; Mehmood A; Siddiqui AM
    J Ayub Med Coll Abbottabad; 2007; 19(3):22-4. PubMed ID: 18444585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Should patients with type 2 diabetes and raised liver enzymes be referred for further evaluation of liver disease?
    Hickman IJ; Russell AJ; Prins JB; Macdonald GA
    Diabetes Res Clin Pract; 2008 Apr; 80(1):e10-2. PubMed ID: 18187226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-alcoholic fatty liver disease: factors associated with its presence and onset.
    Miyake T; Kumagi T; Furukawa S; Tokumoto Y; Hirooka M; Abe M; Hiasa Y; Matsuura B; Onji M
    J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():71-8. PubMed ID: 24251708
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Value of AST/ALT ratio as fibrotic predictor in chronic hepatitis C.
    Park G; Jones DB; Katelaris P
    Am J Gastroenterol; 2005 Jul; 100(7):1623-4; author reply 1624. PubMed ID: 15984996
    [No Abstract]   [Full Text] [Related]  

  • 37. Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels.
    Wong VW; Wong GL; Tsang SW; Hui AY; Chan AW; Choi PC; Chim AM; Chu S; Chan FK; Sung JJ; Chan HL
    Aliment Pharmacol Ther; 2009 Feb; 29(4):387-96. PubMed ID: 19035982
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [On the accuracy of laboratory tests in the diagnosis of fatty liver].
    Kaffarnik H; Gross W; Juchems R
    Munch Med Wochenschr; 1967 Jan; 109(4):199-200. PubMed ID: 6071799
    [No Abstract]   [Full Text] [Related]  

  • 39. Hyperlipidemic chicken as a model of non-alcoholic steatohepatitis.
    Ayala I; Castillo AM; Adánez G; Fernández-Rufete A; Pérez BG; Castells MT
    Exp Biol Med (Maywood); 2009 Jan; 234(1):10-6. PubMed ID: 18997102
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A bright liver.
    Hoteit MA; Sanchez W
    Clin Gastroenterol Hepatol; 2008 Sep; 6(9):xxii. PubMed ID: 18514037
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.